acetic acid-(3-propyl-anilide) | 103858-40-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: acetic acid-(3-propyl-anilide)
• 英文别名: Essigsaeure-(3-propyl-anilid)；N-Acetyl-3-propyl-anilin；N-(3-propylphenyl)acetamide
• CAS: 103858-40-8
• 化学式: C₁₁H₁₅NO
• 分子量: 177.246
• InChiKey: FNMCYNUGQOZFMM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  acetic acid-(3-propyl-anilide) 在 盐酸 、 二硫化碳 、 三氯化铝 作用下， 生成 1-(4-amino-2-propyl-phenyl)-ethanone
  参考文献：
  名称：

  Estrogenic Biphenyls. IV. 3′-Alkyl-4-methoxybiphenyl-4′-carboxylic Acids

  摘要：

  DOI：

  10.1246/bcsj.30.958
• 作为产物：
  描述：

  1-硝基-3-丙基-苯 生成 acetic acid-(3-propyl-anilide)
  参考文献：
  名称：

  REPORT OF THE INTERNATIONAL CONSENSUS DEVELOPMENT CONFERENCE ON FEMALE SEXUAL DYSFUNCTION: DEFINITIONS AND CLASSIFICATIONS

  摘要：

  Purpose: Female sexual dysfunction is highly prevalent but not well defined or understood. We evaluated and revised existing definitions and classifications of female sexual dysfunction.Materials and Methods: An interdisciplinary consensus conference panel consisting of 19 experts in female sexual dysfunction selected from 5 countries was convened by the Sexual Function Health Council of the American Foundation for Urologic Disease. A modified Delphi method was used to develop consensus definitions and classifications, and build on the existing framework of the International Classification of Diseases-10 and DSM-TV: Diagnostic and Statistical Manual of Mental Disorders of the American Psychiatric Association, which were limited to consideration of psychiatric disorders.Results: Classifications were expanded to include psychogenic and organic causes of desire, arousal, orgasm and sexual pain disorders. An essential element of the new diagnostic system is the "personal distress" criterion. In particular, new definitions of sexual arousal and hypoactive sexual desire disorders were developed, and a new category of noncoital sexual pain disorder was added. In addition, a new subtyping system for clinical diagnosis was devised. Guidelines for clinical end points and outcomes were proposed, and important research goals and priorities were identified.Conclusions: We recommend use of the new female sexual dysfunction diagnostic and classification system based on physiological as well as psychological pathophysiologies, and a personal distress criterion for most diagnostic categories.

  DOI：

  10.1016/s0022-5347(05)67828-7

文献信息

• 3-METHYLIDENEOXAN-4-ONE COMPOUNDS AND SUBSTITUTED DERIVATIVES THEREOF AS INHIBITORS OF TELOMERASE
  申请人：NORTHWESTERN UNIVERSITY

  公开号：US20210070725A1

  公开（公告）日：2021-03-11

  Disclosed are 3-methylideneoxan-4-one compounds, derivatives thereof, and methods of their synthesis and methods of their use in treating a disease or disorder in a subject in need thereof, such as diseases and disorders that are associated with telomerase activity such as cancer. The disclosed compounds may be formulated in a pharmaceutical composition for treating diseases and disorders that are associated with telomerase activity such as cancer.

  本文披露了3-甲基亚氧杂环丙烯-4-酮化合物及其衍生物，以及它们的合成方法和在治疗患有疾病或障碍的受试者中的使用方法，例如与端粒酶活性相关的疾病和障碍，如癌症。披露的化合物可以制成药物组合物，用于治疗与端粒酶活性相关的疾病和障碍，如癌症。
• FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS
  申请人：Hangeland Jon J.

  公开号：US20090036438A1

  公开（公告）日：2009-02-05

  The present invention provides a method for treating a thrombotic or an inflammatory disorder administering to a patient in need thereof a therapeutically effective amount of at least one compound of Formula (I) or Formula (V): or a stereoisomer or pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, L, Z, R 3 , R 4 , R 6 , R 11 , X 1 , X 2 , and X 3 are as defined herein. The compounds of Formula (I) are useful as selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; for example thrombin, factor Xa, factor XIa, factor IXa, factor VIIa and/or plasma kallikrein. In particular, it relates to compounds that are selective factor XIa inhibitors. This invention also provides compounds within the scope of Formula I and relates to pharmaceutical compositions comprising these compounds.

  本发明提供了一种治疗血栓性或炎症性疾病的方法，该方法向需要治疗的患者施用至少一种公式（I）或公式（V）中的化合物的治疗有效量：或其立体异构体或药学上可接受的盐或溶剂形式，其中变量A、L、Z、R3、R4、R6、R11、X1、X2和X3如本文所定义。公式（I）的化合物可用作凝血级联和/或接触激活系统的丝氨酸蛋白酶酶的选择性抑制剂；例如凝血酶、因子Xa、因子XIa、因子IXa、因子VIIa和/或血浆激肽。特别是，涉及到选择性因子XIa抑制剂的化合物。本发明还提供了公式I范围内的化合物，并涉及包含这些化合物的制药组合物。
• 3-methylideneoxan-4-one compounds and substituted derivatives thereof as inhibitors of telomerase
  申请人：NORTHWESTERN UNIVERSITY

  公开号：US11518750B2

  公开（公告）日：2022-12-06

  Disclosed are 3-methylideneoxan-4-one compounds, derivatives thereof, and methods of their synthesis and methods of their use in treating a disease or disorder in a subject in need thereof, such as diseases and disorders that are associated with telomerase activity such as cancer. The disclosed compounds may be formulated in a pharmaceutical composition for treating diseases and disorders that are associated with telomerase activity such as cancer.

  本发明公开了3-亚甲基氧杂环己烷-4-酮化合物、其衍生物及其合成方法和用于治疗有需要的受试者的疾病或失调的方法，例如与端粒酶活性相关的疾病和失调，如癌症。所公开的化合物可配制成药物组合物，用于治疗与端粒酶活性相关的疾病和紊乱，如癌症。
• PIPERAZINE, PIPERIDINE AND TETRAHYDROPYRIDINE DERIVATIVES OF INDOL-3-YLALKYL AS 5-HT1D-ALPHA AGONISTS
  申请人：MERCK SHARP & DOHME LTD.

  公开号：EP0759918A1

  公开（公告）日：1997-03-05
• US5807857A
  申请人：——

  公开号：US5807857A

  公开（公告）日：1998-09-15